Venous Leg Ulcers (Crural ulcer) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Venous Leg Ulcers (Crural ulcer) – Pipeline Review, H1 2017’, provides an overview of the Venous Leg Ulcers (Crural ulcer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)

The report reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Venous Leg Ulcers (Crural ulcer) therapeutics and enlists all their major and minor projects

The report assesses Venous Leg Ulcers (Crural ulcer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adocia

CardioVascular BioTherapeutics Inc

CytoTools AG

Factor Therapeutics Ltd

FirstString Research Inc

Mallinckrodt Plc

MediWound Ltd

NovaLead Pharma Pvt Ltd

Promore Pharma

RegeneRx Biopharmaceuticals Inc

RMB-Research GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Venous Leg Ulcers (Crural ulcer) - Overview

Venous Leg Ulcers (Crural ulcer) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development

Adocia

CardioVascular BioTherapeutics Inc

CytoTools AG

Factor Therapeutics Ltd

FirstString Research Inc

Mallinckrodt Plc

MediWound Ltd

NovaLead Pharma Pvt Ltd

Promore Pharma

RegeneRx Biopharmaceuticals Inc

RMB-Research GmbH

Venous Leg Ulcers (Crural ulcer) - Drug Profiles

AUP-16 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biochaperone PDGF-BB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CL-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CODA-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CureXcell - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVBT-141B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EscharEx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granexin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LL-37 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLP-328 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGN-137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-42909 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Statmicoll - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Venous Leg Ulcers (Crural ulcer) - Dormant Projects

Venous Leg Ulcers (Crural ulcer) - Discontinued Products

Venous Leg Ulcers (Crural ulcer) - Product Development Milestones

Featured News & Press Releases

Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update

Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001)

Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US

Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board

May 23, 2016: CytoTools confirms the clinical efficacy of DermaPro in phase II/III trial

Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update

Aug 19, 2015: Macrocure Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell in Venous Leg Ulcers

Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment

Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results

Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications

May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication

Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers

Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results

Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Venous Leg Ulcers (Crural ulcer) – Pipeline by Adocia, H1 2017

Venous Leg Ulcers (Crural ulcer) – Pipeline by CardioVascular BioTherapeutics Inc, H1 2017

Venous Leg Ulcers (Crural ulcer) – Pipeline by CytoTools AG, H1 2017

Venous Leg Ulcers (Crural ulcer) – Pipeline by Factor Therapeutics Ltd, H1 2017

Venous Leg Ulcers (Crural ulcer) – Pipeline by FirstString Research Inc, H1 2017

Venous Leg Ulcers (Crural ulcer) – Pipeline by Mallinckrodt Plc, H1 2017

Venous Leg Ulcers (Crural ulcer) – Pipeline by MediWound Ltd, H1 2017

Venous Leg Ulcers (Crural ulcer) – Pipeline by NovaLead Pharma Pvt Ltd, H1 2017

Venous Leg Ulcers (Crural ulcer) – Pipeline by Promore Pharma, H1 2017

Venous Leg Ulcers (Crural ulcer) – Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017

Venous Leg Ulcers (Crural ulcer) – Pipeline by RMB-Research GmbH, H1 2017

Venous Leg Ulcers (Crural ulcer) – Dormant Projects, H1 2017

Venous Leg Ulcers (Crural ulcer) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports